Stockscreener 앱 받기
1.13
8.13%
-0.10
전일 마감가:
$1.23
열려 있는:
$1.24
하루 거래량:
90,082
Relative Volume:
1.11
시가총액:
$31.15M
수익:
-
순이익/손실:
$-37.38M
주가수익비율:
-0.9059
EPS:
-1.2474
순현금흐름:
$-35.50M
1주 성능:
-16.30%
1개월 성능:
-13.08%
6개월 성능:
-7.38%
1년 성능:
+4.63%
1일 변동 폭
$1.12
$1.24
1주일 범위
$1.12
$1.35
52주 변동 폭
$0.975
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
명칭
An 2 Therapeutics Inc
전화
(650) 331-9090
주소
1800 EL CAMINO REAL, SUITE D, MENLO PARK
ANTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.14 | 33.61M | 0 | -37.38M | -35.50M | -1.2474 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.18 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.37 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.51 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
825.40 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.32 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2024-08-09 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-12 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-01-04 | 개시 | JMP Securities | Mkt Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
모두보기
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Rein Therapeutics (NASDAQ: RNTX) to resume Phase 2 IPF trial; U.S. enrollment at 20 sites - Stock Titan
2,541,781 Restricted Stock Units of Cognition Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 2-NOV-2025. - MarketScreener
KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan
Kyverna Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to - GlobeNewswire
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - Yahoo Finance
Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program - Business Wire
RAPT Therapeutics, Inc. (RAPT) Discusses Top Line Phase II Results for RPT-904 in Chronic Spontaneous UrticariaSlideshow (NASDAQ:RAPT) 2025-10-20 - Seeking Alpha
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) - The Manila Times
RAPT Therapeutics to Report Topline Data from Phase 2 - GlobeNewswire
Monopar Therapeutics Inc. Announces Oral Presentation at AASLD 2025 for Phase 2 Study on Tiomolybdate Choline in Wilson Disease - Quiver Quantitative
Tvardi Therapeutics, Inc. Updates on Phase 2 REVERT Trial Results - TradingView
Denali Therapeutics Announces FDA Review Extension of BLA - GlobeNewswire
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025 - Yahoo Finance
Aarvik Therapeutics Announces Investment by Laurus Labs in Aarvik Series Seed 2 Round - Business Wire
Lexeo Therapeutics, Inc. (LXEO) Special CallSlideshow (NASDAQ:LXEO) 2025-10-07 - Seeking Alpha
Lyra Therapeutics Announces Clinical Plan for LYR-210 and - GlobeNewswire
Viking Therapeutics Stock: A Speculative Buy (NASDAQ:VKTX) - Seeking Alpha
Cellphire Therapeutics announces CRYPTICS Phase 2/3 Clinical Study Final Topline Results - GlobeNewswire
Mineralys Therapeutics Completes Enrollment in Phase 2 EXPLORE-OSA Trial of Lorundrostat in Obstructive Sleep Apnea and Hypertension - GlobeNewswire
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire
Aarvik Therapeutics Announces Successful Series Seed 2 Financing Round - Business Wire
Viking Therapeutics: Overdue For Gains (NASDAQ:VKTX) - Seeking Alpha
United Therapeutics Corporation (UTHR) Phase 3 TETON-2 ResultsSlideshow - Seeking Alpha
Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial - MSN
UPDATE -- ADvantage Therapeutics Awarded $2.5 Million NIH SBIR Grant to Advance Alzheimer’s Drug Candidate AD04® Toward the Clinic - GlobeNewswire
Phase 2 Colorectal Cancer Trial Results: Leap Therapeutics' Sirexatamab Study Data Coming at ESMO 2025 - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Advances Oncology and CNS Therapies with Promising Phase 2 Data - Yahoo Finance
Allarity Therapeutics Presents New Phase 2 Clinical Data - GlobeNewswire
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis - PR Newswire
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe - GlobeNewswire
United Therapeutics' TETON-2 Trial Shows Success in IPF Treatment | UTHR Stock News - Stock Titan
skip to main content - United Therapeutics Investor Relations
Shareholders of Unicycive Therapeutics, Inc. Should Contact - GlobeNewswire
Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer - PR Newswire
Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome - The Malaysian Reserve
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial - GlobeNewswire
EASD 2025 | HighTide Therapeutics Announces Oral Presentation of Phase 3 Data in Patients with Type 2 Diabetes - FinancialContent
Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results - MSN
Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025 - The Manila Times
Kyverna Therapeutics to Highlight Interim Phase 2 Data from - GlobeNewswire
Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA - GlobeNewswire
BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis - sg.finance.yahoo.com
Defence Therapeutics Inc. announced that it has received CAD 2 million in funding - MarketScreener
Institutional investors own a significant stake of 34% in Avalo Therapeutics, Inc. (NASDAQ:AVTX) - Yahoo
Dianthus Therapeutics (DNTH) Is Up 40.2% After Positive Phase 2 Myasthenia Gravis Data and $251M Equity Raise - sg.finance.yahoo.com
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewswire
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025 - Business Wire
Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress - GlobeNewswire
An 2 Therapeutics Inc (ANTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.16%
자본화:
|
볼륨(24시간):